RA
UTHR icon

Riversedge Advisors’s United Therapeutics UTHR Stock Holding History

Riversedge Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-414
Closed -$202K – 249
2025
Q4 		$202K Buy
+414
New +$193K 0.03% 206

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Riversedge Advisors's UTHR Position: Q1 2026 in Review

Riversedge Advisors sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 414 shares — an estimated $202K sold.

Riversedge Advisors first reported a position in UTHR in Q4 2025 and held it in 1 quarter. The position peaked at $202K in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Riversedge Advisors reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Riversedge Advisors sold 414 United Therapeutics shares in Q1 2026, an estimated $202K.
  • Riversedge Advisors first reported a position in United Therapeutics in Q4 2025 and held it in 1 quarter.
  • Riversedge Advisors's United Therapeutics position peaked at $202K in Q4 2025.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Riversedge Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.